Erratum.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 217, doi. 10.1177/1758834017695909
- Publication type:
- Article
Works matching IS 17588340 AND DT 2017 AND VI 9 AND IP 3
Results: 7
1
2
Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 159, doi. 10.1177/1758834016688816
- By:
- Publication type:
- Article
3
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 201, doi. 10.1177/1758834016687262
- By:
- Publication type:
- Article
4
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 183, doi. 10.1177/1758834016683905
- By:
- Publication type:
- Article
5
Nivolumab in renal cell carcinoma: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 171, doi. 10.1177/1758834016679942
- By:
- Publication type:
- Article
6
Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 147, doi. 10.1177/1758834016678375
- By:
- Publication type:
- Article
7
Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 189, doi. 10.1177/1758834016678149
- By:
- Publication type:
- Article